SCHEMBL3549258

SCHEMBL3549258

CCOC(=O)C(c1cc(N2CCN(C)CC2)ccc1NC(C)=O)C(C(N)=O)c1cc(N2CCN(C)CC2)ccc1NC(C)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 5/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
NR4A1 P22736 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HTR6 P50406 2/20 0.39
MAPK1 P28482 3/20 0.38
LMNA P02545 2/20 0.38
NPC1 O15118 2/20 0.38
TP53 P04637 1/20 0.38
HDAC3 O15379 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
LRRK2 Q5S007 1/20 0.38
EGFR P00533 1/20 0.38
TMEM97 Q5BJF2 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3559065 0.80 SIRT6 (0.52) MAPTSMN1; SMN2HTR6MAPK1LMNA
SCHEMBL3546530 0.75 MAPT (0.43) MEN1KMT2AMAPTALOX15ALOX12
SCHEMBL3504979 0.72 HDAC3 (0.60) MEN1KMT2AMAPTHTR6MAPK1
SCHEMBL3547211 0.72 HDAC3 (0.44) MEN1KMT2AMAPTHTR6MAPK1
SCHEMBL3503526 0.70 EGFR (0.61) KMT2AMAPTHTR6MAPK1NPC1
SCHEMBL990479 0.69 SMO (0.43) MEN1KMT2ASMN1; SMN2MAPK1LMNA
SCHEMBL12766942 0.68 HTR6 (0.57) KMT2AMAPTHTR6MAPK1NPC1
SCHEMBL3504890 0.67 EGFR (0.48) HTR6NPC1HDAC3HDAC8EGFR
SCHEMBL21753620 0.66 MAPT (0.61) MAPTHTR6MAPK1ALDH1A1L3MBTL1
SCHEMBL990003 0.66 MAPT (0.41) MEN1KMT2AMAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1747216-B1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2014-01-08 EP disclosed
US-7851475-B2 Substituted pyrrole-2, 5-diones as protein kinase C inhibitors NOVARTIS AG (CH) 2010-12-14 US disclosed
US-20090221605-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2009-09-03 US disclosed
EP-1747216-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS Novartis Pharma AG. (CH) 2007-01-31 EP disclosed
WO-2005113545-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221605-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS PRKCA, PRKCB, PRKCE MEN1 4544/4885KMT2A 2383/4885MAPT 3711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.